Overview
46,XX difference of sex development (DSD) induced by fetoplacental androgen excess is a rare condition in which a baby who is genetically female (with two X chromosomes) is born with external genitalia that appear more masculine or ambiguous. This happens because during pregnancy, the placenta or the developing baby produces unusually high levels of androgens (male-type hormones), which affect how the external genitals form. The internal reproductive organs — the uterus, fallopian tubes, and ovaries — are typically normal and female because the excess androgens only influence development during a specific window of fetal growth. This condition is sometimes called fetoplacental hyperandrogenism-related 46,XX DSD. It is distinct from other causes of virilization in genetic females, such as congenital adrenal hyperplasia (CAH), which is the most common cause. In this particular form, the androgen excess comes specifically from the fetoplacental unit rather than the baby's adrenal glands. The degree of genital ambiguity can range from mild clitoral enlargement to more significant masculinization. Diagnosis typically involves hormone testing, genetic analysis, and imaging to confirm the presence of normal female internal structures. Treatment depends on the degree of virilization and may include surgical correction of the genitalia if needed, hormone monitoring, and psychological support. Because the source of excess androgens is the placenta or fetal tissues during pregnancy, the condition does not usually continue to cause problems after birth, and most affected individuals can expect normal puberty and fertility with appropriate care.
Also known as:
Key symptoms:
Ambiguous genitalia at birthEnlarged clitorisPartially fused labia (outer genital folds joined together)Genitalia that appear more masculine than expected for a female babyNormal internal female organs (uterus and ovaries)Possible darkening of genital skinNo signs of salt-wasting or adrenal crisis (unlike congenital adrenal hyperplasia)
Sporadic
Usually appears on its own, not inherited from a parent
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for 46,XX difference of sex development induced by fetoplacental androgens excess.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for 46,XX difference of sex development induced by fetoplacental androgens excess at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for 46,XX difference of sex development induced by fetoplacental androgens excess.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to 46,XX difference of sex development induced by fetoplacental androgens excess.
Community
No community posts yet. Be the first to share your experience with 46,XX difference of sex development induced by fetoplacental androgens excess.
Start the conversation →Latest news about 46,XX difference of sex development induced by fetoplacental androgens excess
No recent news articles for 46,XX difference of sex development induced by fetoplacental androgens excess.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What is the exact cause of the androgen excess in my child's case?,Does my child have normal internal female organs, and what tests confirmed this?,Is surgery recommended, and if so, what are the risks and benefits of waiting?,Will my child need hormone therapy at puberty or at any other time?,What are the expected outcomes for fertility and sexual function?,Should we pursue genetic testing for aromatase deficiency or other specific genes?,Can you refer us to a psychologist experienced with differences of sex development?
Common questions about 46,XX difference of sex development induced by fetoplacental androgens excess
What is 46,XX difference of sex development induced by fetoplacental androgens excess?
46,XX difference of sex development (DSD) induced by fetoplacental androgen excess is a rare condition in which a baby who is genetically female (with two X chromosomes) is born with external genitalia that appear more masculine or ambiguous. This happens because during pregnancy, the placenta or the developing baby produces unusually high levels of androgens (male-type hormones), which affect how the external genitals form. The internal reproductive organs — the uterus, fallopian tubes, and ovaries — are typically normal and female because the excess androgens only influence development durin
How is 46,XX difference of sex development induced by fetoplacental androgens excess inherited?
46,XX difference of sex development induced by fetoplacental androgens excess follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does 46,XX difference of sex development induced by fetoplacental androgens excess typically begin?
Typical onset of 46,XX difference of sex development induced by fetoplacental androgens excess is neonatal. Age of onset can vary across affected individuals.